ArticleScientific reports2025
Therapeutic potential of greenly synthesized selenium nanoparticles against experimental cyclosporiasis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biogenic synthesis and characterization of selenium nanoparticles by halotolerant Bacillus sonorensis 2MNHR.Applied microbiology and biotechnology · 2026Article
- Green synthesis of selenium nanoparticles using Bacillus sp. strain STG-83: optimization, characterization, and prospects for cancer radiosensitization.Scientific reports · 2026Article
- Development and Characterization of a Guar Gum Bionanocomposite Loaded with Biogenic Selenium Nanoparticles and Its Cytotoxic Evaluation.Gels (Basel, Switzerland) · 2026Article
- Green synthesis of silver nanoparticles by isolated Bacillus velezensis BS1 and their applications.Applied microbiology and biotechnology · 2026Article
- Studying the potential ameliorative effect of biosynthesized selenium nanoparticles using epigallocatechin gallate against depression in rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclospora cayetanensis (C. cayetanensis), an opportunistic intracellular coccidian, is responsible for chronic debilitating diarrheal outbreaks possessing life-threatening penalties, especially in immunocompromised patients. The solemn therapeutic agents against cyclosporiasis are limited by their grave effects and high recurrence rate. The current study aimed to utilize greenly synthesized selenium nanoparticles (SeNPs) and evaluate their therapeutic efficacy on cyclosporiasis in immunosuppressed murine models. They were biosynthesized proficiently using Alcaligenes faecalis and characterized by assorted analytical techniques. After molecular confirmation of the parasite strain, immunosuppressed mice were infected with 10,000 C. cayetanensis sporulated oocysts. The anti-Cyclospora activity of seven-day oral treatment of 10 mg/kg of SeNPs was assessed through parasitological, ultrastructural, histopathological, and biochemical studies. The in vivo safety of SeNPs was assessed clinically, biochemically, and histopathologically. Parasitologically, SeNPs recorded the highest statistically significant decrease in the fecal oocyst burden (97.96%R) on the 30th day post-infection (PI). Scanning electron microscopic examination revealed remarkably deformed SeNPs-treated oocysts. SeNPs-treated mice exhibited impressive amelioration in intestinal architecture and inflammation, protracted to the 30th day PI. Colorimetric analysis revealed that SeNPs have recorded the highest serum reduced glutathione (GSH) level (300% increase) that swiftly repressed malondialdehyde (MDA) by 63.46%R. The present work has shed the first light on biogenic SeNPs as a safe, promising, proficient antioxidant nanotherapeutic for the treatment of experimental cyclosporiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.